Proteomic profiles of CRS following treatment with liso-cel and ide-cel

CRB-401 18-month follow-up: influence of T-cell profile on outcome of ide-cel treatment in myelomaПодробнее

Long-Term Efficacy and Safety of Cilta-Cel in Patients With Relapsed/Refractory Multiple MyelomaПодробнее

$Long-Term Efficacy and Safety of Cilta-Cel in Patients With Relapsed/Refractory Multiple Myeloma$

The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-celПодробнее

Characteristics of neurotoxicity associated with ide-cel in pts with RRMM in phase II KarMMaПодробнее

RCC Update from ESMO 2023Подробнее

Impact of age on ide-cel efficacy in the KarMMa trialПодробнее

Impact of ide-cel and future directionsПодробнее

What is ide-cel and how can it benefit myeloma patients?Подробнее

Multiomics profiling of MRD to understand the biology of drug resistance in multiple myelomaПодробнее

Comparing efficacy outcomes of ide-cel versus conventional care in R/R myelomaПодробнее

Updates on ide-cel and cilta-cel for myelomaПодробнее

3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCLПодробнее

Further improvements of ide-cel therapy in KarMMa trialsПодробнее

Isoplexis and UF | ICBR Monoclonal Antibody SeminarПодробнее

What is Bloodflow and how can it improve MRD assessment in MM?Подробнее

Determinants of response to quadruplet therapy in multiple myeloma: genomic determinants & NK cellsПодробнее

Vulnerabilities in lipid synthesis pathways and resistance to IMiDs and CELMoDs in multiple myelomaПодробнее

Transforming Medicine Qu Biologics' Innovative Immunomodulation.Подробнее